Sam Whiting MD PhD

Sam Whiting MD PhD has worked in the medical field since 2005. Sam began their career as an Assistant Member in the Clinical Research Division at the Fred Hutchinson Cancer Research Center. In 2006, they became an Assistant Professor in the Division of Medical Oncology at the University of Washington. In 2011, they were appointed Clinical Director of Gastrointestinal Oncology at the University of Washington and Seattle Cancer Care Alliance. In 2012, they became the Director of Clinical Research at Oncothyreon, Inc. In 2014, they were appointed Vice President of Research and Clinical Development at Gradalis Inc. and Senior Medical Director at VentiRx. Sam also served as Director of Developmental Therapeutics at Mary Crowley Cancer Research Centers during this time. In 2016, they were promoted to Senior Vice President of Clinical Development and Vice President of Clinical Development at Calithera Biosciences. Most recently, in 2020, they became Executive Vice President and Chief Medical Officer at Tempest Therapeutics.

Sam Whiting MD PhD completed their education history with a Medical Oncology certification from the American Board of Internal Medicine. Prior to this, they obtained an MD PhD from the NIH Medical Scientist Training Program (MSTP) at the University of Washington - School of Medicine. Sam also completed a Medical Specialty in ABIM Research Pathway Internal Medicine at the same institution. Additionally, they completed a Medical Subspecialty in ABIM Research Pathway Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center. Before this, they obtained a Bachelor's Degree in Chemistry from Lewis & Clark College between 1985 and 1989. Theireducation history began at Lake Oswego High School.